- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07599059
AI-Assisted Ultrasound Therapy for Adhesive Capsulitis
Artificial Intelligence-Assisted Dynamic Imaging Analysis and Predictive Modeling of Ultrasound-Guided Capsular Distension Therapy for Adhesive Capsulitis
This study aims to integrate artificial intelligence with ultrasound imaging to investigate the dynamic biomechanical characteristics of adhesive capsulitis and to compare the therapeutic effectiveness of three ultrasound-guided hydrodilatation techniques: rotator interval injection, dual-target injection, and posterior glenohumeral injection. In the observational phase, healthy participants and patients with adhesive capsulitis will undergo static and dynamic ultrasound evaluations to quantify subacromial motion and the minimal vertical acromiohumeral distance (mvAHD) during shoulder abduction. A Faster R-CNN model will automatically identify the acromion and greater tuberosity to extract motion trajectories and frequency-based features.
In the randomized clinical trial phase, patients will be assigned to one of the three hydrodilatation techniques to compare improvements in pain, function, and range of motion at 6 and 12 weeks. All participants will subsequently enter a one-year follow-up to document recurrence, defined as the need for repeat intervention. Clinical characteristics, static sonographic parameters, dynamic motion metrics, and short-term treatment responses will be incorporated into machine-learning models to predict long-term outcomes, including recurrence risk. Eligible patients who decline randomization may consent to join a parallel observational cohort. They will receive standard-of-care treatment (conservative or interventional) based on their preference, and undergo the exact same baseline, Week 6, and Week 12 clinical and ultrasound assessments as the randomized trial participants.
The ultimate goal is to establish an AI-assisted predictive framework that enables individualized risk stratification, early identification of poor responders, and optimization of injection strategies. This model is expected to improve clinical decision-making, enhance treatment precision, and contribute to higher-quality patient care.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Taipei, Taïwan
- National Taiwan University Hospital, Bei-Hu Branch
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Inclusion Criteria for the Control Group:
- Age-matched adults (≥ 18 years old) with no symptoms of adhesive capsulitis.
- Age distribution matched with that of the disease group.
Inclusion Criteria for the Disease Group (Adhesive Capsulitis):
- Shoulder stiffness persisting for more than one month.
Restriction of passive range of motion by more than 30° in at least two of the three directions (forward flexion, abduction, and external rotation) compared to the contralateral side, with imaging findings consistent with the diagnostic features of primary adhesive capsulitis.
Exclusion Criteria:
Exclusion Criteria (for both Control and Disease Groups):
- Systemic rheumatic disease (like rheumatoid arthritis and ankylosing spondylitis).
- History of malignancy.
- Previous major trauma, surgeries, or recent injection therapy on the affected shoulder.
- Suprascapular nerve block within the previous three months.
- Inability to clearly understand or express personal willingness due to central nervous system injury.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Rotator Interval Injection
|
An ultrasound-guided injection administered through the rotator interval approach.
|
|
Expérimental: Dual-Target Injecton
|
An ultrasound-guided injection targeting both the rotator interval and the subdeltoid bursa.
|
|
Expérimental: Posterior Recess Injection
|
An injection into the glenohumeral joint utilizing a posterior approach.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in Shoulder Pain and Disability Index (SPADI) Total Score
Délai: Baseline, Week 6, and Week 12
|
Shoulder Pain and Disability Index:
|
Baseline, Week 6, and Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in Shoulder Range of Motion (ROM)
Délai: Baseline, Week 6, and Week 12
|
Baseline, Week 6, and Week 12
|
|
|
Incidence of Treatment-Related Adverse Events
Délai: Up to Week 12
|
Up to Week 12
|
|
|
Change from Baseline in Visual Analog Scale (VAS) for Pain
Délai: Baseline, Week 6, and Week 12
|
Visual Analogue Scale:
|
Baseline, Week 6, and Week 12
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 202512151RIND
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .